{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:20:27Z","timestamp":1779272427562,"version":"3.51.4"},"reference-count":186,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013507","name":"Oskar Huttunen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007123","name":"The Stanley Medical Research Institute","doi-asserted-by":"publisher","award":["O7R-1888"],"award-info":[{"award-number":["O7R-1888"]}],"id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.phrs.2025.107633","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T19:16:35Z","timestamp":1738091795000},"page":"107633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["IUPHAR review: Drug repurposing in Schizophrenia \u2013 An updated review of clinical trials"],"prefix":"10.1016","volume":"213","author":[{"given":"Jihan K.","family":"Zaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Tomasik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Bahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.107633_bib1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41380-021-01161-7","article-title":"Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies","volume":"27","author":"Solmi","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib2","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","article-title":"Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019","volume":"28","author":"Solmi","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib3","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of Schizophrenia: findings from the global burden of disease study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2025.107633_bib4","first-page":"357","article-title":"Global economic burden of schizophrenia: a systematic review","volume":"12","author":"Chong","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.phrs.2025.107633_bib5","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/schbul\/sbs130","article-title":"A systematic review and meta-analysis of recovery in Schizophrenia","volume":"39","author":"J\u00e4\u00e4skel\u00e4inen","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2025.107633_bib6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.31887\/DCNS.2014.16.4\/mcarbon","article-title":"Clinical predictors of therapeutic response to antipsychotics in schizophrenia","volume":"16","author":"Carbon","year":"2014","journal-title":"Dialog-. Clin. Neurosci."},{"key":"10.1016\/j.phrs.2025.107633_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105454","article-title":"An umbrella review of adverse effects associated with antipsychotic medications: the need for complementary study designs","volume":"155","author":"Chow","year":"2023","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.phrs.2025.107633_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-3-031-21054-9_11","article-title":"The difficult path to the discovery of novel treatments in psychiatric diseases","volume":"30","author":"Gribkoff","year":"2023","journal-title":"Adv. Neurobiol."},{"key":"10.1016\/j.phrs.2025.107633_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1749-6632.2011.06216.x","article-title":"Advancing drug discovery for schizophrenia","volume":"1236","author":"Marder","year":"2011","journal-title":"Ann. N. Y Acad. Sci."},{"key":"10.1016\/j.phrs.2025.107633_bib10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III--the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2025.107633_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J. Health Econ."},{"key":"10.1016\/j.phrs.2025.107633_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/schizbullopen\/sgae018","article-title":"Biomarkers for psychosis: are we there yet? Umbrella review of 1478 biomarkers","volume":"5","author":"Fuentes-Claramonte","year":"2024","journal-title":"Schizophr. Bull. Open"},{"key":"10.1016\/j.phrs.2025.107633_bib13","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","article-title":"Mapping genomic loci implicates genes and synaptic biology in schizophrenia","volume":"604","author":"Trubetskoy","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107633_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102473","article-title":"Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis","volume":"69","author":"Etchecopar-Etchart","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.phrs.2025.107633_bib15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1021\/acschemneuro.8b00205","article-title":"Clinical trials and therapeutic rationale for drug repurposing in schizophrenia","volume":"10","author":"Lago","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.phrs.2025.107633_bib16","unstructured":"Trends and Charts on Registered Studies | ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/about-site\/trends-charts\u3009 (Accessed December 15, 2024)."},{"key":"10.1016\/j.phrs.2025.107633_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.schres.2014.07.025","article-title":"Neuroimmune biomarkers in schizophrenia","volume":"176","author":"Tomasik","year":"2016","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.phrs.2025.107633_bib18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.bbi.2020.08.012","article-title":"A characterization of the molecular phenotype and inflammatory response of schizophrenia patient-derived microglia-like cells","volume":"90","author":"Ormel","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.phrs.2025.107633_bib19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bbi.2017.10.003","article-title":"Evidence of microglial activation following exposure to serum from first-onset drug-na\u00efve schizophrenia patients","volume":"67","author":"van Rees","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.phrs.2025.107633_bib20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pharmthera.2018.05.005","article-title":"Autoimmune phenotypes in schizophrenia reveal novel treatment targets","volume":"189","author":"Severance","year":"2018","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.phrs.2025.107633_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.schres.2021.05.014","article-title":"Prenatal infection and schizophrenia: a decade of further progress","volume":"247","author":"Cheslack-Postava","year":"2022","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.phrs.2025.107633_bib22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/schbul\/sbj052","article-title":"Prenatal infection as a risk factor for schizophrenia","volume":"32","author":"Brown","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2025.107633_bib23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Ripke","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107633_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature16549","article-title":"Schizophrenia risk from complex variation of complement component 4","volume":"530","author":"Sekar","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107633_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-021-01596-0","article-title":"Autoantibody profiles associated with clinical features in psychotic disorders","volume":"11","author":"Jernbom Falk","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib26","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/s41380-018-0123-4","article-title":"Exploring the neuropsychiatric spectrum using high-content functional analysis of single-cell signaling networks","volume":"25","author":"Lago","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S2215-0366(19)30290-1","article-title":"Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin","volume":"7","author":"Pollak","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.biopsych.2018.06.016","article-title":"Associations between non-neurological autoimmune disorders and psychosis: a meta-analysis","volume":"85","author":"Cullen","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jpsychires.2022.12.003","article-title":"Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: two open-label pilot studies on treatment-resistant patients","volume":"158","author":"Bejerot","year":"2023","journal-title":"J. Psychiatr. Res"},{"key":"10.1016\/j.phrs.2025.107633_bib30","article-title":"Immunomodulatory treatment may change functional and structural brain imaging in severe mental disorders","volume":"41","author":"Thunberg","year":"2024","journal-title":"Brain Behav. Immun. Health"},{"key":"10.1016\/j.phrs.2025.107633_bib31","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1164\/ajrccm.159.2.9804085","article-title":"Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages","volume":"159","author":"Marques","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.phrs.2025.107633_bib32","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1097\/HJH.0000000000001086","article-title":"Effects of pentoxifylline on inflammatory markers and blood pressure: a systematic review and meta-analysis of randomized controlled trials","volume":"34","author":"Brie","year":"2016","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2025.107633_bib33","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/02698811231186760","article-title":"Pentoxifylline as adjunctive therapy in cognitive deficits and symptoms of schizophrenia: a randomized double-blind placebo-controlled clinical trial","volume":"37","author":"Sinichi","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.phrs.2025.107633_bib34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/cns.14010","article-title":"Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: a double-blind, randomized, placebo-controlled trial","volume":"29","author":"Abdallah","year":"2023","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.phrs.2025.107633_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers","volume":"70","author":"Raison","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.euroneuro.2022.05.001","article-title":"Sodium nitroprusside enhances the antipsychotic-like effect of olanzapine but not clozapine in the conditioned avoidance response test in rats","volume":"60","author":"Titulaer","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2025.107633_bib37","doi-asserted-by":"crossref","DOI":"10.1186\/s12868-015-0149-3","article-title":"Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia","volume":"16","author":"Kandratavicius","year":"2015","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.phrs.2025.107633_bib38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.schres.2014.12.035","article-title":"Nitroprusside single-dose prevents the psychosis-like behavior induced by ketamine in rats for up to one week","volume":"162","author":"Maia-de-Oliveira","year":"2015","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.phrs.2025.107633_bib39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.schres.2021.03.005","article-title":"Treatment-resistant schizophrenia - a RCT on the effectiveness of repeated-dose sodium nitroprusside","volume":"231","author":"Adelino","year":"2021","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.phrs.2025.107633_bib40","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamapsychiatry.2019.0151","article-title":"Efficacy and tolerability of adjunctive intravenous sodium nitroprusside treatment for outpatients with schizophrenia: a randomized clinical trial","volume":"76","author":"Brown","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib41","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamapsychiatry.2019.0151","article-title":"Efficacy and tolerability of adjunctive intravenous sodium nitroprusside treatment for outpatients with schizophrenia: a randomized clinical trial","volume":"76","author":"Brown","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib42","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1017\/S0033291716002245","article-title":"The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Stone","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.phrs.2025.107633_bib43","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamapsychiatry.2013.1292","article-title":"Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial","volume":"70","author":"Hallak","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1271624","article-title":"The efficacy and safety of sodium nitroprusside in the treatment of schizophrenia: a meta-analysis","volume":"14","author":"Fei","year":"2023","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/acps.12799","article-title":"The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia","volume":"136","author":"Fan","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.phrs.2025.107633_bib46","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00213-019-5181-z","article-title":"Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial","volume":"236","author":"Fan","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2025.107633_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-010-2002-9","article-title":"Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine","volume":"213","author":"Yamashita","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2025.107633_bib48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.schres.2021.01.024","article-title":"The effect of prednisolone on symptom severity in schizophrenia: a placebo-controlled, randomized controlled trial","volume":"230","author":"Nasib","year":"2021","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.phrs.2025.107633_bib49","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-020-04365-4","article-title":"Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design","volume":"21","author":"Nasib","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.phrs.2025.107633_bib50","unstructured":"M. Thomas, J. Raedler, 2008, The Muscarinic Hypothesis of Schizophrenia, vol. 25\u3008https:\/\/www.psychiatrictimes.com\/view\/muscarinic-hypothesis-schizophrenia\u3009(Accessed November 19, 2024).."},{"key":"10.1016\/j.phrs.2025.107633_bib51","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.schres.2024.11.001","article-title":"Muscarinic deficits - part of a cholinergic-dopaminergic- glutamatergic imbalance in schizophrenia?","volume":"274","author":"Keshavan","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.phrs.2025.107633_bib52","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S2215-0366(24)00100-7","article-title":"Psychosis as a disorder of muscarinic signalling: psychopathology and pharmacology","volume":"11","author":"McCutcheon","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib53","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1471-4159.2008.05711.x","article-title":"Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?","volume":"107","author":"Scarr","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.phrs.2025.107633_bib54","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.mp.4001924","article-title":"Towards a muscarinic hypothesis of schizophrenia","volume":"12","author":"Raedler","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib55","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/mp.2008.28","article-title":"Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia","volume":"14","author":"Scarr","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib56","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.160.1.118","article-title":"In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia","volume":"160","author":"Raedler","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib57","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/npp.2015.189","article-title":"Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model","volume":"41","author":"Ghoshal","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2025.107633_bib58","unstructured":"FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia | FDA, (n.d.). \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-drug-new-mechanism-action-treatment-schizophrenia\u3009 (Accessed November 13, 2024)."},{"key":"10.1016\/j.phrs.2025.107633_bib59","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer Disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.phrs.2025.107633_bib60","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib61","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","article-title":"Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia","volume":"179","author":"Paul","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib62","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline\u2013trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107633_bib63","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00345-003-0321-8","article-title":"Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability","volume":"20","author":"Halaska","year":"2003","journal-title":"World J. Urol."},{"key":"10.1016\/j.phrs.2025.107633_bib64","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis","volume":"62","author":"Siskind","year":"2017","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-022-02254-9","article-title":"Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study","volume":"12","author":"Sauder","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.schres.2024.08.001","article-title":"Efficacy of KarXT on negative symptoms in acute schizophrenia: a post hoc analysis of pooled data from 3 trials","volume":"274","author":"Horan","year":"2024","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.phrs.2025.107633_bib67","first-page":"47","article-title":"The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue","volume":"5","author":"Brisch","year":"2014","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib68","doi-asserted-by":"crossref","first-page":"12330","DOI":"10.1523\/JNEUROSCI.2808-11.2011","article-title":"Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia","volume":"31","author":"Valenti","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2025.107633_bib69","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1523\/JNEUROSCI.03-08-01607.1983","article-title":"Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons","volume":"3","author":"Chiodo","year":"1983","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2025.107633_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113201","article-title":"Targeting muscarinic receptors to treat schizophrenia","volume":"405","author":"Foster","year":"2021","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.phrs.2025.107633_bib71","unstructured":"AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia - Nov 11, 2024, (n.d.). \u3008https:\/\/news.abbvie.com\/2024-11-11-AbbVie-Provides-Update-on-Phase-2-Results-for-Emraclidine-in-Schizophrenia\u3009 (Accessed December 15, 2024)."},{"key":"10.1016\/j.phrs.2025.107633_bib72","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/S0140-6736(22)01990-0","article-title":"Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial","volume":"400","author":"Krystal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107633_bib73","first-page":"367","article-title":"Memantine: a review of studies into its safety and efficacy in treating Alzheimer\u2019s disease and other dementias","volume":"4","author":"Thomas","year":"2009","journal-title":"Clin. Inter. Aging"},{"key":"10.1016\/j.phrs.2025.107633_bib74","doi-asserted-by":"crossref","first-page":"11569","DOI":"10.4088\/JCP.17f11998","article-title":"Memantine as an Augmentation treatment for schizophrenia: limitations of meta-analysis for evidence-based evaluation of research","volume":"78","author":"Andrade","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib75","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1017\/S0033291717001271","article-title":"Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"48","author":"Zheng","year":"2018","journal-title":"Psychol. Med"},{"key":"10.1016\/j.phrs.2025.107633_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102473","article-title":"Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis","volume":"69","author":"Etchecopar-Etchart","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.phrs.2025.107633_bib77","doi-asserted-by":"crossref","first-page":"e1307","DOI":"10.4088\/JCP.17f11998","article-title":"Memantine as an augmentation treatment for schizophrenia: limitations of meta-analysis for evidence-based evaluation of research","volume":"78","author":"Andrade","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib78","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s11481-012-9382-z","article-title":"Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan","volume":"7","author":"Chen","year":"2012","journal-title":"J. Neuroimmune Pharm."},{"key":"10.1016\/j.phrs.2025.107633_bib79","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jpsychires.2015.07.027","article-title":"ALDH2 polymorphism, associated with attenuating negative symptoms in patients with schizophrenia treated with add-on dextromethorphan","volume":"69","author":"Lee","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.phrs.2025.107633_bib80","doi-asserted-by":"crossref","first-page":"609","DOI":"10.9758\/cpn.23.1081","article-title":"Dextromethorphan-bupropion (Auvelity) for the treatment of major depressive disorder","volume":"21","author":"McCarthy","year":"2023","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.phrs.2025.107633_bib81","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/PL00005241","article-title":"Riluzole, a glutamate release inhibitor, and motor behavior","volume":"358","author":"Kretschmer","year":"1998","journal-title":"Naunyn Schmiede Arch. Pharm."},{"key":"10.1016\/j.phrs.2025.107633_bib82","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00213-013-3261-z","article-title":"A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia","volume":"231","author":"Farokhnia","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2025.107633_bib83","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00213-019-5188-5","article-title":"Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications","volume":"236","author":"Pillinger","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2025.107633_bib84","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s12264-015-1555-3","article-title":"Clemastine rescues behavioral changes and enhances remyelination in the cuprizone mouse model of demyelination","volume":"31","author":"Li","year":"2015","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.phrs.2025.107633_bib85","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/schbul\/sbad065","article-title":"Disturbed oligodendroglial maturation causes cognitive dysfunction in schizophrenia: a new hypothesis","volume":"49","author":"Falkai","year":"2023","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2025.107633_bib86","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0140-6736(03)14289-4","article-title":"Oligodendrocyte dysfunction in schizophrenia and bipolar disorder","volume":"362","author":"Tkachev","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107633_bib87","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pneurobio.2010.09.004","article-title":"Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia","volume":"93","author":"Takahashi","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.phrs.2025.107633_bib88","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1161\/STROKEAHA.124.047154","article-title":"Nimodipine protects vascular and cognitive function in an animal model of cerebral small vessel disease","volume":"55","author":"Yang","year":"2024","journal-title":"Stroke"},{"key":"10.1016\/j.phrs.2025.107633_bib89","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.2147\/DDDT.S248115","article-title":"Nimodipine improves cognitive impairment after subarachnoid hemorrhage in rats through IncRNA NEAT1\/miR-27a\/MAPT Axis","volume":"14","author":"Li","year":"2020","journal-title":"Drug Des. Devel Ther."},{"key":"10.1016\/j.phrs.2025.107633_bib90","article-title":"Nimodipine for primary degenerative, mixed and vascular dementia","volume":"2002","author":"Birks","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2025.107633_bib91","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/mp.2009.49","article-title":"The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia","volume":"15","author":"Green","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib92","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau9093","article-title":"Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo","volume":"5","author":"Lago","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2025.107633_bib93","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.seizure.2023.03.017","article-title":"Levetiracetam, from broad-spectrum use to precision prescription: a narrative review and expert opinion","volume":"107","author":"Celdran de Castro","year":"2023","journal-title":"Seizure - Eur. J. Epilepsy"},{"key":"10.1016\/j.phrs.2025.107633_bib94","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/YIC.0000000000000405","article-title":"Can levetiracetam improve clinical symptoms in schizophrenic patients? A randomized placebo-controlled clinical trial","volume":"37","author":"Behdani","year":"2022","journal-title":"Int Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2025.107633_bib95","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41386-023-01730-0","article-title":"Modulation of hippocampal activity in schizophrenia with levetiracetam: a randomized, double-blind, cross-over, placebo-controlled trial","volume":"49","author":"Roeske","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2025.107633_bib96","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.seizure.2022.12.002","article-title":"Levetiracetam induces severe psychiatric symptoms in people with epilepsy","volume":"116","author":"Tao","year":"2024","journal-title":"Seizure. Eur. J. Epilepsy"},{"key":"10.1016\/j.phrs.2025.107633_bib97","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/jamaneurol.2018.4561","article-title":"Prediction tools for psychiatric adverse effects after levetiracetam prescription","volume":"76","author":"Josephson","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.phrs.2025.107633_bib98","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.schres.2020.07.004","article-title":"The effects of lorazepam on cortico-striatal connectivity in schizophrenia","volume":"223","author":"Ali","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.phrs.2025.107633_bib99","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1038\/s41380-020-0711-y","article-title":"GABA-A receptor differences in schizophrenia: a positron emission tomography study using [11C]Ro154513","volume":"26","author":"Marques","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib100","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fpsyt.2017.00118","article-title":"GABAergic mechanisms in schizophrenia: linking postmortem and in vivo studies","volume":"8","author":"de Jonge","year":"2017","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib101","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00124509-200412000-00007","article-title":"Etomidate versus propofol for electroconvulsive therapy in patients with schizophrenia","volume":"20","author":"Gazdag","year":"2004","journal-title":"J. ECT"},{"key":"10.1016\/j.phrs.2025.107633_bib102","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/eb-2017-102624","article-title":"Short-term adjunct of topiramate to antipsychotics in schizophrenia improves the psychopathology and has weight maintenance","volume":"20","author":"Kishi","year":"2017","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.phrs.2025.107633_bib103","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/13651501.2018.1449864","article-title":"Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials","volume":"23","author":"Goh","year":"2019","journal-title":"Int J. Psychiatry Clin. Pr."},{"key":"10.1016\/j.phrs.2025.107633_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2021.102963","article-title":"Randomised, placebo-controlled trial on topiramate add-on therapy for weight reduction and symptomatology in overweight\/obese persons with schizophrenia","volume":"68","author":"Chandradasa","year":"2022","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.phrs.2025.107633_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.00693","article-title":"Schizophrenia and sex hormones: what is the link?","volume":"11","author":"Brzezinski-Sinai","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib106","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/B978-0-12-800981-9.00027-4","article-title":"Hormones and schizophrenia","volume":"23","author":"Kulkarni","year":"2016","journal-title":"Handb. Behav. Neurosci."},{"key":"10.1016\/j.phrs.2025.107633_bib107","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/schbul\/sbt105","article-title":"Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways","volume":"40","author":"Schwarz","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2025.107633_bib108","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.psyneuen.2010.12.018","article-title":"Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia","volume":"36","author":"Guest","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.phrs.2025.107633_bib109","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/acps.13530","article-title":"Estradiol and raloxifene as adjunctive treatment for women with schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"147","author":"Li","year":"2023","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.phrs.2025.107633_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2020.104830","article-title":"Bazedoxifene - a promising brain active SERM that crosses the blood brain barrier and enhances spatial memory","volume":"121","author":"Hill","year":"2020","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.phrs.2025.107633_bib111","doi-asserted-by":"crossref","DOI":"10.1007\/s00737-023-01409-x","article-title":"Estrogen and psychosis - a review and future directions","volume":"27","author":"Mu","year":"2024","journal-title":"Arch. Women\u2019s. Ment. Health"},{"key":"10.1016\/j.phrs.2025.107633_bib112","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.psyneuen.2018.02.004","article-title":"Pregnenolone-progesterone-allopregnanolone pathway as a potential therapeutic target in first-episode antipsychotic-na\u00efve patients with schizophrenia","volume":"90","author":"Cai","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.phrs.2025.107633_bib113","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(62)91477-0","article-title":"Insulin treatment of schizophrenia. A three-year follow-up of a controlled study","author":"Ackner","year":"1962","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107633_bib114","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(57)91070-X","article-title":"Insulin treatment of schizophrenia; a controlled study","volume":"272","author":"Ackner","year":"1957","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107633_bib115","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.psyneuen.2012.09.009","article-title":"Schizophrenia: metabolic aspects of aetiology, diagnosis and future treatment strategies","volume":"38","author":"Harris","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.phrs.2025.107633_bib116","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib117","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jamapsychiatry.2016.3803","article-title":"Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis","volume":"74","author":"Pillinger","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib118","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.psyneuen.2010.12.018","article-title":"Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia","volume":"36","author":"Guest","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.phrs.2025.107633_bib119","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamapsychiatry.2019.0304","article-title":"Association of insulin resistance with schizophrenia polygenic risk score and response to antipsychotic treatment","volume":"76","author":"Tomasik","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib120","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1038\/s41380-023-02065-4","article-title":"Insulin effects on core neurotransmitter pathways involved in schizophrenia neurobiology: a meta-analysis of preclinical studies. Implications for the treatment","volume":"28","author":"de Bartolomeis","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106860","article-title":"Central and peripheral actions of nicotine that influence blood glucose homeostasis and the development of diabetes","volume":"194","author":"Chen","year":"2023","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107633_bib122","unstructured":"FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 | FDA, (n.d.). \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-chronic-weight-management-first-2014\u3009 (Accessed November 20, 2024)."},{"key":"10.1016\/j.phrs.2025.107633_bib123","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.metabol.2013.09.010","article-title":"Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells","volume":"63","author":"Lee","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2025.107633_bib124","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212585","article-title":"Clinical potential of treatment with semaglutide in type 2 diabetes patients","volume":"8","author":"R\u00f8der","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.phrs.2025.107633_bib125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2024.04.041","article-title":"Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"222","author":"Moiz","year":"2024","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2025.107633_bib126","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.3390\/ijms25094972","article-title":"A systematic review of semaglutide\u2019s influence on cognitive function in preclinical animal models and cell-line studies","volume":"25","author":"Tipa","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107633_bib127","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/bph.15508","article-title":"Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders","volume":"179","author":"H\u00f6lscher","year":"2022","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.phrs.2025.107633_bib128","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1038\/s41380-023-02065-4","article-title":"Insulin effects on core neurotransmitter pathways involved in schizophrenia neurobiology: a meta-analysis of preclinical studies. Implications for the treatment","volume":"28","author":"de Bartolomeis","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.mito.2020.11.009","article-title":"Mitochondrial dysfunction in schizophrenia: With a focus on postmortem studies","volume":"56","author":"Roberts","year":"2021","journal-title":"Mitochondrion"},{"key":"10.1016\/j.phrs.2025.107633_bib130","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fnins.2015.00372","article-title":"The role of inflammation in schizophrenia","volume":"9","author":"M\u00fcller","year":"2015","journal-title":"Front Neurosci."},{"key":"10.1016\/j.phrs.2025.107633_bib131","doi-asserted-by":"crossref","DOI":"10.1093\/schizbullopen\/sgaa044","article-title":"Leptin serum levels are associated with glp-1 receptor agonist-mediated effects on glucose metabolism in clozapine- or olanzapine-treated, prediabetic, schizophrenia patients","volume":"1","author":"Tomasik","year":"2020","journal-title":"Schizophr. Bull. Open"},{"key":"10.1016\/j.phrs.2025.107633_bib132","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231165169","article-title":"Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin \u2013 a case series","volume":"13","author":"Prasad","year":"2023","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.phrs.2025.107633_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102726","article-title":"12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study","volume":"74","author":"De Giorgi","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.phrs.2025.107633_bib134","doi-asserted-by":"crossref","first-page":"47","DOI":"10.24869\/psyd.2024.47","article-title":"Effect of vortioxetine on the quality of life in patients with schizophrenia","volume":"36","author":"Gre\u0161","year":"2024","journal-title":"Psychiatr. Danub"},{"key":"10.1016\/j.phrs.2025.107633_bib135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/00912174231199925","article-title":"The effect of vortioxetine on anhedonia in patients with schizophrenia","volume":"59","author":"Gre\u0161","year":"2024","journal-title":"Int. J. Psychiatry Med."},{"key":"10.1016\/j.phrs.2025.107633_bib136","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/JCP.0000000000001242","article-title":"Vortioxetine on cognition in schizophrenia: a pilot study","volume":"40","author":"Bruno","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2025.107633_bib137","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/0269881120909416","article-title":"Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: a randomised, double-blind, placebo-controlled clinical trial","volume":"34","author":"Moazen-Zadeh","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.phrs.2025.107633_bib138","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/JCP.0000000000000587","article-title":"Agomelatine for the treatment of major depressive episodes in schizophrenia-spectrum disorders: an open-prospective proof-of-concept study","volume":"36","author":"Englisch","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2025.107633_bib139","first-page":"700","article-title":"Bromocriptine-induced schizophrenia","volume":"85","author":"Peter","year":"1993","journal-title":"J. Natl. Med Assoc."},{"key":"10.1016\/j.phrs.2025.107633_bib140","first-page":"252","article-title":"Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia","volume":"43","author":"Frye","year":"1982","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib141","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/08039488.2015.1094127","article-title":"Bromocriptine mitigated paliperidone metabolic and neuro-hormonal side effects and improved negative domain in a case of early onset schizophrenia","volume":"70","author":"Naguy","year":"2016","journal-title":"Nord J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib142","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0165-1781(83)90059-8","article-title":"Bromocriptine therapy in chronic schizophrenia: effects on symptomatology, sleep patterns, and prolactin response to stimulation","volume":"8","author":"Brambilla","year":"1983","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.phrs.2025.107633_bib143","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/496416a","article-title":"Mental health: on the spectrum","volume":"496","author":"Adam","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107633_bib144","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/2167702613497473","article-title":"The p factor: one general psychopathology factor in the structure of psychiatric disorders?","volume":"2","author":"Caspi","year":"2014","journal-title":"Clin. Psychol. Sci."},{"key":"10.1016\/j.phrs.2025.107633_bib145","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/s41380-018-0123-4","article-title":"Exploring the neuropsychiatric spectrum using high-content functional analysis of single-cell signaling networks","volume":"25","author":"Lago","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib146","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9949453","article-title":"N-acetylcysteine: a review of clinical usefulness (an Old Drug with New Tricks)","volume":"2021","author":"Schwalfenberg","year":"2021","journal-title":"J. Nutr. Metab."},{"key":"10.1016\/j.phrs.2025.107633_bib147","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/jpm13111526","article-title":"Schizophrenia and glutathione: a challenging story","volume":"13","author":"Carletti","year":"2023","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.phrs.2025.107633_bib148","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/sj.mp.4001511","article-title":"Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress","volume":"9","author":"Prabakaran","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib149","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1089\/ars.2010.3459","article-title":"The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics","volume":"15","author":"Martins-De-Souza","year":"2011","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.phrs.2025.107633_bib150","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/acps.12862","article-title":"N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials","volume":"137","author":"Zheng","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.phrs.2025.107633_bib151","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0004867419893439","article-title":"Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia","volume":"54","author":"Yolland","year":"2020","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib152","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.schres.2015.01.033","article-title":"A systematic review of the antipsychotic properties of cannabidiol in humans","volume":"162","author":"Iseger","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.phrs.2025.107633_bib153","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2215-0366(20)30074-2","article-title":"Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis","volume":"7","author":"Hindley","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib154","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41386-022-01478-z","article-title":"Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios","volume":"48","author":"Englund","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2025.107633_bib155","doi-asserted-by":"crossref","first-page":"37517","DOI":"10.52965\/001c.37517","article-title":"Buprenorphine and its formulations: a comprehensive review","volume":"10","author":"Poliwoda","year":"2022","journal-title":"Health Psychol. Res."},{"key":"10.1016\/j.phrs.2025.107633_bib156","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.biopsych.2019.05.012","article-title":"The role of dynorphin and the kappa opioid receptor in the symptomatology of schizophrenia: a review of the evidence","volume":"86","author":"Clark","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib157","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41386-020-0730-z","article-title":"Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials","volume":"45","author":"Clark","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2025.107633_bib158","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1176\/ajp.144.10.1340","article-title":"Antipsychotic effect of buprenorphine in schizophrenia","volume":"144","author":"Schmauss","year":"1987","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib159","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hup.470060113","article-title":"Buprenorphine and Schizophrenia","volume":"6","author":"Groves","year":"1991","journal-title":"Hum. Psychopharmacol.: Clin. Exp."},{"key":"10.1016\/j.phrs.2025.107633_bib160","doi-asserted-by":"crossref","first-page":"18861","DOI":"10.4088\/JCP.13m08725","article-title":"Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults","volume":"75","author":"Karp","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib161","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/appi.ajp.2015.15070921","article-title":"Opioid modulation with buprenorphine\/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial","volume":"173","author":"Fava","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib162","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.3390\/ijms19082410","article-title":"The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review","volume":"19","author":"Serafini","year":"2018","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107633_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.bionps.2024.100107","article-title":"Biomarker discovery using machine learning in the psychosis spectrum","volume":"11","author":"Yassin","year":"2024","journal-title":"Biomark. Neuropsychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/gm429","article-title":"Proteomic profiling in schizophrenia: enabling stratification for more effective treatment","volume":"5","author":"Guest","year":"2013","journal-title":"Genome Med"},{"key":"10.1016\/j.phrs.2025.107633_bib165","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.ajhg.2022.07.011","article-title":"Genetics-informed precision treatment formulation in schizophrenia and bipolar disorder","volume":"109","author":"Reay","year":"2022","journal-title":"Am. J. Hum. Genet"},{"key":"10.1016\/j.phrs.2025.107633_bib166","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi7293","article-title":"Deep learning-based integration of genetics with registry data for stratification of schizophrenia and depression","volume":"8","author":"Alles\u00f8e","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2025.107633_bib167","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41380-021-01201-2","article-title":"Integrative omics of schizophrenia: from genetic determinants to clinical classification and risk prediction","volume":"27","author":"Guan","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib168","article-title":"Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study","volume":"9","author":"Martinuzzi","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib169","first-page":"1","article-title":"Clustering of cognitive subtypes in schizophrenia patients and their siblings: relationship with regional brain volumes","volume":"8","author":"Alkan","year":"2022","journal-title":"Schizophrenia"},{"key":"10.1016\/j.phrs.2025.107633_bib170","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.schres.2019.05.044","article-title":"Identifying schizophrenia subgroups using clustering and supervised learning","volume":"214","author":"Talpalaru","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.phrs.2025.107633_bib171","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.schres.2022.06.021","article-title":"Cluster analysis of negative symptoms identifies distinct negative symptom subgroups","volume":"246","author":"Paul","year":"2022","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.phrs.2025.107633_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103274","article-title":"Symptom-based patient stratification in mental illness using clinical notes","volume":"98","author":"Liu","year":"2019","journal-title":"J. Biomed. Inf."},{"key":"10.1016\/j.phrs.2025.107633_bib173","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpsychires.2021.05.078","article-title":"Evaluation of IGF-1 as a novel theranostic biomarker for schizophrenia","volume":"140","author":"Yesilkaya","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.phrs.2025.107633_bib174","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.schres.2024.02.011","article-title":"Exploring peripheral biomarkers of response to simvastatin supplementation in schizophrenia","volume":"266","author":"Zaki","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.phrs.2025.107633_bib175","doi-asserted-by":"crossref","DOI":"10.1093\/schizbullopen\/sgaa044","article-title":"Leptin serum levels are associated With GLP-1 receptor agonist-mediated effects on glucose metabolism in clozapine- or olanzapine-treated, prediabetic, schizophrenia patients","volume":"1","author":"Tomasik","year":"2020","journal-title":"Schizophr. Bull. Open"},{"key":"10.1016\/j.phrs.2025.107633_bib176","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"Fleming","year":"2012","journal-title":"Stat. Med."},{"key":"10.1016\/j.phrs.2025.107633_bib177","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107633_bib178","doi-asserted-by":"crossref","DOI":"10.1038\/s41537-023-00356-x","article-title":"Influencing factors of medication adherence in schizophrenic patients: a meta-analysis","volume":"9","author":"Guo","year":"2023","journal-title":"Schizophrenia"},{"key":"10.1016\/j.phrs.2025.107633_bib179","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.phrs.2025.107633_bib180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-48307-w","article-title":"Potentially repurposable drugs for schizophrenia identified from its interactome","volume":"9","author":"Karunakaran","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2025.107633_bib181","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/npjschz.2016.12","article-title":"Schizophrenia interactome with 504 novel protein\u2013protein interactions","volume":"2","author":"Ganapathiraju","year":"2016","journal-title":"NPJ Schizophr."},{"key":"10.1016\/j.phrs.2025.107633_bib182","doi-asserted-by":"crossref","DOI":"10.1038\/s41525-022-00290-4","article-title":"The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets","volume":"7","author":"Lago","year":"2022","journal-title":"NPJ Genom. Med."},{"key":"10.1016\/j.phrs.2025.107633_bib183","first-page":"1","article-title":"From understanding diseases to drug design: can artificial intelligence bridge the gap?","volume":"57","author":"Pushkaran","year":"2024","journal-title":"Artif. Intell. Rev."},{"key":"10.1016\/j.phrs.2025.107633_bib184","first-page":"1","article-title":"A foundation model for clinician-centered drug repurposing","author":"Huang","year":"2024","journal-title":"Nat. Med"},{"key":"10.1016\/j.phrs.2025.107633_bib185","unstructured":"TxGNN Explorer, (n.d.). http:\/\/txgnn.org\/ (Accessed December 2, 2024)."},{"key":"10.1016\/j.phrs.2025.107633_bib186","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41597-023-01960-3","article-title":"Building a knowledge graph to enable precision medicine","volume":"10","author":"Chandak","year":"2023","journal-title":"Sci. Data"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825000581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825000581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:44:17Z","timestamp":1762353857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825000581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":186,"alternative-id":["S1043661825000581"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107633","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IUPHAR review: Drug repurposing in Schizophrenia \u2013 An updated review of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107633"}}